UK markets open in 4 hours 8 minutes
  • NIKKEI 225

    +836.48 (+2.19%)

    -48.85 (-0.29%)

    -0.40 (-0.51%)

    +4.70 (+0.23%)
  • DOW

    +456.87 (+1.18%)
  • Bitcoin GBP

    -455.64 (-1.12%)
  • CMC Crypto 200

    0.00 (0.00%)
  • NASDAQ Composite

    +460.72 (+2.96%)
  • UK FTSE All Share

    +14.98 (+0.36%)

Albumin Excipient Market to Reach $6.32 Billion by 2028, Driven by Chronic Disease Prevalence and Healthcare Expenditure

Company Logo
Company Logo

Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "Albumin Excipient Global Market Report 2024" report has been added to's offering.

The albumin excipient market, a critical component of the biopharmaceutical industry, is expected to continue its robust growth trajectory, reaching an anticipated $6.32 billion by the year 2028. This notable rise represents a compound annual growth rate (CAGR) of 6.5% from 2024, fueled by the increasing prevalence of chronic diseases and a surge in global healthcare expenditures.

According to the latest market research, the biopharmaceutical sector's expansion, coupled with innovations in drug delivery systems, is significantly contributing to the market's growth. Chronic conditions such as cancer and diabetes have necessitated the development of advanced therapeutic options, where albumin plays a fundamental role due to its biocompatibility and capability to enhance the efficacy of peptide and protein-based drugs.

Key Market Drivers:

  • An increase in chronic diseases necessitating advanced treatment options

  • Greater healthcare spending facilitating research and development

  • Collaborative efforts and partnerships augmenting innovation

A recent market analysis identifies North America as the dominant player in the global albumin excipient landscape. However, the Asia-Pacific region is poised to record the fastest growth during the forecast period. This is attributable to escalating healthcare initiatives and burgeoning investments in the biopharmaceutical sector within these emerging economies.

Emerging Trends:

  • The upsurge in the utilization of human serum albumin and recombinant albumin products

  • Strategic acquisitions enhancing the capabilities of key market players

  • Innovation in product offerings catering to a diverse range of healthcare needs

Respected for their versatile applications across pharmaceuticals and biotechnology industries, albumin excipients stand as indispensable tools for research institutes and various health-related endeavors.

The comprehensive market overview provided in the research spans integral components such as market size, regional shares, competitive landscapes, and segmentation by product types and end-users. This exhaustive market research report furnishes stakeholders with valuable insights into the market dynamics and future outlook of the albumin excipient industry.

Amidst the prevailing trends, companies within the albumin excipient market are pursuing novel strategies to cement their market positions, including the adoption of sustainable and biodegradable albumin-based formulations. The emphasis on regulatory compliance and stringent quality standards underlines the market's commitment to excellence and innovation.

The research encapsulates the essence of the albumin excipient market, articulating its fundamental economic drivers, pinpointing the current market concerns, and discerning the prospective opportunities. Its in-depth analysis solidifies its status as an invaluable resource for industry leaders, healthcare professionals, and market analysts keen on making informed decisions in this dynamic market landscape.

Moreover, the albumin excipient market study consistently reflects upon the key components, from end-user applications to anticipated market adjustments, propelling the albumin excipient domain forward.

The Albumin Excipient Market: A Beacon of Growth in Biopharmaceuticals

The albumin excipient market stands as a testament to the relentless pursuit of medical advancement, underscoring the synergy between healthcare expenditure and the escalation of chronic illnesses. Its growth signifies the relentless stride of innovation, leading to improved clinical outcomes and, fundamentally, a higher standard of patient care.

Remarkably, the market research report does not solely present the current state but projects a future where albumin excipients continue to break new ground in therapeutic applications and drug delivery. The industry's foothold in biopharmaceuticals evidences an unwavering focus on elevating the quality of life for patients worldwide.

A selection of companies mentioned in this report includes

  • Albumin Therapeutics LLC

  • Biotest AG

  • CSL Behring

  • Grifols S.A.

  • HiMedia Laboratories LLC

  • InVitria Inc.

  • Medxbio Pte Ltd.

  • Octapharma AG

  • RayBiotech Inc.

  • SeraCare Life Sciences Inc.

  • Sigma-Aldrich Pty. Ltd.

  • Hualan Biological Engineering Inc.

  • Kedrion Biopharma

  • LFB USA Inc.

  • Shanghai RAAS Blood Products Co. Ltd.

  • Baxter International Inc.

  • Bristol-Myers Squibb Company

  • Merck KGaA

  • Thermo Fisher Scientific Inc.

  • Albumedix A/S

  • Bio Products Laboratory Ltd.

  • Shire Plc.

  • Ventria Bioscience Inc.

  • Novartis AG

  • China Biologic Products Holdings Inc.

  • ProMetic Life Sciences Inc.

  • Sanquin

  • Biopharma

  • Takeda Pharmaceutical Company Limited

  • FUJIFILM Irvine Scientific Inc.

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900